Clinical Trial Update: Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris [Phase 2]

View source ↗

Summary

Phase 2 trial of adenovirus VEGF-D gene therapy (AdvVEGF-D) for refractory angina pectoris has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease

Drugs mentioned

• AdvVEGF-D (VEGF-D gene therapy using an adenoviral vector)

Snippet

Sponsor: Kuopio University Hospital | Conditions: Refractory Angina Pectoris, Gene Transfer | Phase 2 | Status: COMPLETED